-
1
-
-
0028202869
-
-
Sugaya, T.; Mimura, Y.; Shida, Y.; Osawa, Y.; Matsukuma, I.; Ikeda, S.; Akinaga, S.; Morimoto, M.; Ashizawa, T.; Okabe, M.; Ohno, H.; Gomi, K.; Kasai, M. J. Med. Chem. 1994, 37, 1028.
-
(1994)
J. Med. Chem.
, vol.37
, pp. 1028
-
-
Sugaya, T.1
Mimura, Y.2
Shida, Y.3
Osawa, Y.4
Matsukuma, I.5
Ikeda, S.6
Akinaga, S.7
Morimoto, M.8
Ashizawa, T.9
Okabe, M.10
Ohno, H.11
Gomi, K.12
Kasai, M.13
-
2
-
-
0344380652
-
-
Abstracts No. 110, Salt Lake City, Utah, USA
-
a) Ikeda, S.; Mimura, Y.; Sugaya, T.; Nakamura, A.; Ashizawa, T.; Akinaga, S.; Ohno, H.; Okabe, M.; Gomi, K.; Kasai, M. In 24th National Medicinal Chemistry Symposium; Abstracts No. 110, Salt Lake City, Utah, USA, 1994.
-
(1994)
24th National Medicinal Chemistry Symposium
-
-
Ikeda, S.1
Mimura, Y.2
Sugaya, T.3
Nakamura, A.4
Ashizawa, T.5
Akinaga, S.6
Ohno, H.7
Okabe, M.8
Gomi, K.9
Kasai, M.10
-
3
-
-
0344380647
-
-
U.S. Patent 5220026, 1993; Eur. Patent 487097A1, 1992
-
b) Mimura, Y.; Shida, Y.; Kasai, M.; Ashizawa, T.; Gomi, K. U.S. Patent 5220026, 1993; Eur. Patent 487097A1, 1992; Chem. Abstr. 1992, 117, 90167.
-
(1992)
Chem. Abstr.
, vol.117
, pp. 90167
-
-
Mimura, Y.1
Shida, Y.2
Kasai, M.3
Ashizawa, T.4
Gomi, K.5
-
4
-
-
0031946083
-
-
Ashizawa, T.; Shimizu, M.; Gomi, K.; Okabe, M. Anti-Cancer Drugs 1998, 9, 263.
-
(1998)
Anti-Cancer Drugs
, vol.9
, pp. 263
-
-
Ashizawa, T.1
Shimizu, M.2
Gomi, K.3
Okabe, M.4
-
5
-
-
0028323438
-
-
Sugaya, T.; Mimura, Y.; Kato, N.; Ikuta, M.; Mimura, T.; Kasai, M.; Tomioka, S. Synthesis 1994, 73.
-
(1994)
Synthesis
, pp. 73
-
-
Sugaya, T.1
Mimura, Y.2
Kato, N.3
Ikuta, M.4
Mimura, T.5
Kasai, M.6
Tomioka, S.7
-
6
-
-
0030748628
-
-
Kato, N.; Sugaya, T.; Mimura, T.; Ikuta, M.; Kato, S.; Kuge, Y.; Tomioka, S.; Kasai, M. Synthesis 1997, 625.
-
(1997)
Synthesis
, pp. 625
-
-
Kato, N.1
Sugaya, T.2
Mimura, T.3
Ikuta, M.4
Kato, S.5
Kuge, Y.6
Tomioka, S.7
Kasai, M.8
-
7
-
-
85088712424
-
-
2O=6/1, pH 2.7 adjusted with 85% phosphoric acid; flow rate: 1.0 mL/min; detection: UV 254 nm
-
2O=6/1, pH 2.7 adjusted with 85% phosphoric acid; flow rate: 1.0 mL/min; detection: UV 254 nm.
-
-
-
-
8
-
-
85088713797
-
-
note
-
3. This method was too diluted and very inefficient for the production, so a new efficient reducing method was required.
-
-
-
-
9
-
-
33845278140
-
-
Evans, D. A.; Chapman, K. T.; Carreira, E. M. J. Am. Chem. Soc. 1988, 110, 3560.
-
(1988)
J. Am. Chem. Soc.
, vol.110
, pp. 3560
-
-
Evans, D.A.1
Chapman, K.T.2
Carreira, E.M.3
-
10
-
-
0344812295
-
-
HPLC analysis conditions; column: YMC pack AM-312 ODS 6 × 150 mm; mobile phase: MeCN/phosphate buffer (0.1 mol/ L, pH 2.7)=70/30 and sodium 1-octanesufonate (0.01 mol/L); flow rate: 1.0 mL/min; detection: UV 254 nm
-
HPLC analysis conditions; column: YMC pack AM-312 ODS 6 × 150 mm; mobile phase: MeCN/phosphate buffer (0.1 mol/ L, pH 2.7)=70/30 and sodium 1-octanesufonate (0.01 mol/L); flow rate: 1.0 mL/min; detection: UV 254 nm.
-
-
-
-
11
-
-
0345243429
-
-
HPLC analysis conditions; column: YMC pack AM-312 ODS 6 × 150 mm; mobile phase; MeCN/phosphate buffer (0.1 mol/ L, pH 2.7)=35/65 and sodium 1-octanesufonate (0.01 mol/L); flow rate: 1.0 mL/min; detection: UV 254 nm
-
HPLC analysis conditions; column: YMC pack AM-312 ODS 6 × 150 mm; mobile phase; MeCN/phosphate buffer (0.1 mol/ L, pH 2.7)=35/65 and sodium 1-octanesufonate (0.01 mol/L); flow rate: 1.0 mL/min; detection: UV 254 nm.
-
-
-
-
12
-
-
0344380645
-
-
HPLC analysis conditions; column: YMC pack AM-312 ODS 6 × 150 mm; mobile phase: MeCN/phosphate buffer (0.1 mol/ L, pH 2.7)=30/70 and sodium 1-octanesufonate (0.01 mol/L); flow rate: 1.0 mL/min; detection: UV 254 nm
-
HPLC analysis conditions; column: YMC pack AM-312 ODS 6 × 150 mm; mobile phase: MeCN/phosphate buffer (0.1 mol/ L, pH 2.7)=30/70 and sodium 1-octanesufonate (0.01 mol/L); flow rate: 1.0 mL/min; detection: UV 254 nm.
-
-
-
-
14
-
-
0344380648
-
-
Wakogel-200 was commercially available silica gel from Wako Chemical Co.
-
Wakogel-200 was commercially available silica gel from Wako Chemical Co.
-
-
-
|